Equities Analysts Offer Predictions for Alphatec Q2 Earnings

Alphatec Holdings, Inc. (NASDAQ:ATEC) – Stock analysts at HC Wainwright issued their Q2 2026 earnings per share (EPS) estimates for Alphatec in a research note issued on Wednesday, February 25th. HC Wainwright analyst S. Lee anticipates that the medical technology company will post earnings per share of $0.01 for the quarter. HC Wainwright currently has a “Buy” rating and a $24.00 price target on the stock. The consensus estimate for Alphatec’s current full-year earnings is ($1.08) per share. HC Wainwright also issued estimates for Alphatec’s FY2026 earnings at $0.09 EPS and FY2030 earnings at $1.13 EPS.

Other equities analysts also recently issued research reports about the stock. Needham & Company LLC restated a “buy” rating and set a $22.00 price objective on shares of Alphatec in a research report on Monday, January 12th. Piper Sandler reiterated an “overweight” rating on shares of Alphatec in a research note on Wednesday. Wall Street Zen upgraded shares of Alphatec from a “hold” rating to a “buy” rating in a research report on Saturday, January 31st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alphatec in a report on Monday, December 29th. Finally, TD Cowen reissued a “buy” rating on shares of Alphatec in a research note on Tuesday, January 27th. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $22.82.

Alphatec Price Performance

Shares of NASDAQ ATEC opened at $13.62 on Monday. The stock has a fifty day moving average price of $16.74 and a 200 day moving average price of $17.11. Alphatec has a 1-year low of $8.81 and a 1-year high of $23.29. The company has a debt-to-equity ratio of 40.35, a current ratio of 2.06 and a quick ratio of 1.28. The company has a market cap of $2.06 billion, a PE ratio of -14.34 and a beta of 1.02.

Alphatec (NASDAQ:ATEC) last posted its quarterly earnings data on Tuesday, February 24th. The medical technology company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. The company had revenue of $212.93 million for the quarter, compared to analyst estimates of $212.67 million. The firm’s revenue was up 20.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.23) earnings per share.

Insider Buying and Selling at Alphatec

In related news, CEO Patrick Miles sold 100,000 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $21.01, for a total value of $2,101,000.00. Following the sale, the chief executive officer owned 5,135,398 shares in the company, valued at $107,894,711.98. This represents a 1.91% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Craig E. Hunsaker sold 37,358 shares of Alphatec stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $14.71, for a total value of $549,536.18. Following the transaction, the executive vice president directly owned 1,173,025 shares of the company’s stock, valued at approximately $17,255,197.75. This represents a 3.09% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 1,336,125 shares of company stock worth $27,174,878. Corporate insiders own 22.80% of the company’s stock.

Institutional Investors Weigh In On Alphatec

Large investors have recently added to or reduced their stakes in the business. Aster Capital Management DIFC Ltd acquired a new position in Alphatec during the third quarter worth about $34,000. Osterweis Capital Management Inc. purchased a new position in shares of Alphatec during the 2nd quarter worth approximately $37,000. Northwestern Mutual Wealth Management Co. raised its position in shares of Alphatec by 157.1% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,571 shares of the medical technology company’s stock worth $54,000 after purchasing an additional 1,571 shares during the last quarter. Nisa Investment Advisors LLC raised its position in shares of Alphatec by 22.4% during the 2nd quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company’s stock worth $63,000 after purchasing an additional 1,045 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in Alphatec in the 3rd quarter valued at approximately $73,000. 66.35% of the stock is owned by institutional investors and hedge funds.

About Alphatec

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.